ASP-3082
- Generic Name
- ASP-3082
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: Nanoparticle albumin-bound-paclitaxelDrug: Oxaplatin
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 651
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath